At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
AZD3759drug
Likely dose
AZD3759 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 in Chinese Patients With EGFRm+ NSCLC With Central Nervous System (CNS) Metastases
In Brief
A Phase 2 clinical trial evaluating AZD3759 for Non Small Cell Lung Cancer. Completed, enrolled 15 participants across 4 sites.
Detailed Summary
This is a multi-center, open-label, dose escalation and phase I/II study, consisting of dose escalation in Part A and phase II study in Part B.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
CollaboratorsTigermed Consulting Co., Ltd
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedDec 2017
Primary CompletionNov 2020
TodayJul 2026
First PostedDec 4, 2017
Enrollment StartOct 30, 2017
Primary CompletionNov 13, 2020
TodayJul 1, 2026
Enrollment to primary: 3.0 yearsPosted 8.6 years ago
Interventions
AZD3759drug
Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.